Sanofi is cutting the list price of its insulin in the U.S. by 78%, establishing a $35 monthly cap for the privately insured.
Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday. The change is effective January 1.
Then, Novo Nordisk said Tuesday that it will slash the list prices of several of its popular pre-filled insulin pens and vials by up to 75%. However, the company did not announce an expansion of its programs that cut patients' out-of-pocket costs, which has been a focus of President Joe Biden and congressional Democrats. It runs several programs to lower costs for people with diabetes.
Last year, congressional Democrats passed the Inflation Reduction Act, which reduces Medicare beneficiaries' out-of-pocket cost for insulin to $35 per month per prescription starting this year. Republicans blocked a measure to extend that price cap to those covered by private insurance. Demand for insulin has grown significantly as diabetes has become the fastest-growing chronic disease in the world, a 2022 study found.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Sanofi to cut U.S. insulin prices by up to 78%, capping cost at $35Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78%, the company announced.
Leer más »
Sanofi to cut US price of its most-prescribed insulin by 78%Sanofi SA said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly and Co .
Leer más »
Sanofi to cut US price of its most-prescribed insulin by 78%Sanofi SA said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly and Co .
Leer más »
Sanofi to Cut US Price of Its Most-Prescribed Insulin by 78%Sanofi said on Thursday it will cut US list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly.
Leer más »
Diabetes Drug Giant Sanofi Cuts Insulin Prices by Up to 78%French drugmaker Sanofi SA said it would cut the price of some of its insulin products by as much as 78% in the U.S., joining other big diabetes drugmakers facing pressure over high costs.
Leer más »
Sanofi Is Latest Drugmaker to Cut Insulin PricesSanofi is planning to cut the U.S. price of its most-prescribed insulin by 78% and cap monthly out-of-pocket costs at $35 for people who have private insurance. CNBC
Leer más »